Chang-Ki Min
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chang-Ki Min has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Chun-Choo Kim
Catholic Hematopoietic Stem Cell Transplantation Center, The Catholic University of Korea College of Medicine, Seoul, Korea
1 shared publicationDok Hyun Yoon
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 13 Gangdong-daero, Songpa-gu, Seoul 138-736, Republic of Korea
1 shared publication- Hee-Je Kim
School of Electrical Engineering, Pusan National University, Gumjeong-Ku, Jangjeong-Dong, Busan 46241, South Korea
1 shared publication - Ho Sup Lee
Department of Internal Medicine, Kosin University College of Medicine, 262 Gamcheon-ro, Seo-gu, Busan 602-702, Republic of Korea
1 shared publication Ho-Jin Shin
Department of Internal Medicine, Pusan National University Hospital, 179 Gudeok-ro, Seo-gu, Busan 602-739, Republic of Korea
1 shared publicationHo-Youn Kim
Rheumatism Research Center, Catholic Research Institutes of Medical Science, The Catholic University of Korea College of Medicine, Seoul, Korea
1 shared publication
Latest Publications
- Open Access
- 4 June 2014
- Published by Wiley in BioMed Research International
- Vol. 2014, 1-7
Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenström Macroglobulinemia in Korea
Waldenström’s macroglobulinemia (WM) is a B-cell proliferative malignancy characterized by immunoglobulin M monoclonal gammopathy and bone marrow infiltration by lymphoplasmacytic cells. Clinical features and cytogenetics of WM in Asia including Republic of Korea remain unclear. Moreover, no study has reported treatment outcomes in patients with WM treated with novel agent combined with conventional chemotherapy. This study investigated clinical features and assessed treatment outcomes with novel agent and conventional chemotherapy in Republic of Korea. Data from all () patients with newly diagnosed WM at 17 hospitals who received chemotherapy between January 2005 and December 2012 were collected retrospectively. The median age of patients was 66 years (range: 37–92 years) and male to female ratio was 5 : 1. Patients treated with novel agent combined chemotherapy displayed higher overall response rate (ORR) compared to conventional chemotherapy alone (92.9% versus 52.6%,). The 5-year overall survival rate was 62.6% (95% confidence interval: 34.73–111.07). Use of novel agents produced higher ORR but survival benefit was not apparent due to the small number of patients and short follow-up duration. Further studies are needed to confirm the efficacy of novel agents in patients with WM.- 4 June 2014
- Published by Wiley in BioMed Research International
- Vol. 2014, 1-7
Open AccessClinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenström Macroglobulinemia in Korea
Waldenström’s macroglobulinemia (WM) is a B-cell proliferative malignancy characterized by immunoglobulin M monoclonal gammopathy and bone marrow infiltration by lymphoplasmacytic cells. Clinical features and cytogenetics of WM in Asia including Republic of Korea remain unclear. Moreover, no study has reported treatment outcomes in patients with WM treated with novel agent combined with conventional chemotherapy. This study investigated clinical features and assessed treatment outcomes with novel agent and conventional chemotherapy in Republic of Korea. Data from all () patients with newly diagnosed WM at 17 hospitals who received chemotherapy between January 2005 and December 2012 were collected retrospectively. The median age of patients was 66 years (range: 37–92 years) and male to female ratio was 5 : 1. Patients treated with novel agent combined chemotherapy displayed higher overall response rate (ORR) compared to conventional chemotherapy alone (92.9% versus 52.6%,). The 5-year overall survival rate was 62.6% (95% confidence interval: 34.73–111.07). Use of novel agents produced higher ORR but survival benefit was not apparent due to the small number of patients and short follow-up duration. Further studies are needed to confirm the efficacy of novel agents in patients with WM. - Open Access
- 1 January 2009
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 24 (3) , 252-262
Bone Marrow T Cells are Superior to Splenic T Cells to Induce Chimeric Conversion After Non-Myeloablative Bone Marrow Transplantation
Park HS, et al. Korean J Intern Med. 2009 Sep;24(3):252-262. http://dx.doi.org/10.3904/kjim.2009.24.3.252
- 1 January 2009
- Published by Korean Association of Internal Medicine in The Korean Journal of Internal Medicine
- Vol. 24 (3) , 252-262
Open AccessBone Marrow T Cells are Superior to Splenic T Cells to Induce Chimeric Conversion After Non-Myeloablative Bone Marrow Transplantation
Park HS, et al. Korean J Intern Med. 2009 Sep;24(3):252-262. http://dx.doi.org/10.3904/kjim.2009.24.3.252